DrugPatentWatch Database Preview
ARNUITY ELLIPTA Drug Profile
Which patents cover Arnuity Ellipta, and what generic alternatives are available?
Arnuity Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. There are eight patents protecting this drug.
The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.
Summary for ARNUITY ELLIPTA
Pharmacology for ARNUITY ELLIPTA
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Synonyms for ARNUITY ELLIPTA
| (1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-DIFLUORO-14-{[(FLUOROMETHYL)SULFANYL]CARBONYL}-17-HYDROXY-2,13,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIEN-14-YL FURAN-2-CARBOXYLATE |
| (6|A,11|A,16|A,17|A)-6,9-Difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioic Acid S-(Fluoromethyl) Ester |
| (6alpha,11alpha,14beta,16alpha,17alpha)-6,9-Difluoro-17-{[(Fluoromethyl)sulfanyl]carbonyl}-11-Hydroxy-16-Methyl-3-Oxoandrosta-1,4-Dien-17-Yl Furan-2-Carboxylate |
| 397864-44-7 |
| 6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl 2-furoate |
| 779352-12-4 |
| 911210-90-7 |
| Alisade |
| Allermist |
| Avamys |
| BDBM50354851 |
| CHEBI:74899 |
| DB08906 |
| DTXSID60228586 |
| Flonase Sensimist |
| Flonase Sensimist Allergy Relief |
| Fluticasone fuorate |
| Fluticasone furancarboxylate |
| Fluticasone furoate |
| Fluticasone furoate (JAN/USAN/INN) |
| Fluticasone furoate [USAN:INN] |
| FLUTICASONEFUROATE |
| fluticasonum furoas |
| FT-0668768 |
| Furamist |
| furoate de fluticasone |
| furoato de fluticasona |
| GSK 685 698 |
| GSK 685698 |
| GW 685698 |
| GW 685698X |
| GW-685698 |
| GW-685698X |
| GW6 |
| gw685698 |
| GW685698X |
| JS86977WNV |
| PL010437 |
| SCHEMBL140504 |
| UNII-JS86977WNV |
| Veramyst |
| Veramyst (TN) |
| ZINC3992105 |
US Patents and Regulatory Information for ARNUITY ELLIPTA
Expired US Patents for ARNUITY ELLIPTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-001 | Aug 20, 2014 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Glaxosmithkline | ARNUITY ELLIPTA | fluticasone furoate | POWDER;INHALATION | 205625-002 | Aug 20, 2014 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for ARNUITY ELLIPTA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Australia | 2003244506 | ➤ Try a Free Trial |
| China | 101084030 | ➤ Try a Free Trial |
| United Kingdom | 0019172 | ➤ Try a Free Trial |
| Israel | 177042 | ➤ Try a Free Trial |
| Norway | 333467 | ➤ Try a Free Trial |
| South Africa | 200805029 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for ARNUITY ELLIPTA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB08/026 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111 |
| 429 | Luxembourg | ➤ Try a Free Trial | 91429, EXPIRES: 20230111 |
| 6 | Finland | ➤ Try a Free Trial | |
| C0014 | France | ➤ Try a Free Trial | PRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111 |
| C0067 | France | ➤ Try a Free Trial | PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215 |
| 0343 | Netherlands | ➤ Try a Free Trial | 300343, 20210803, EXPIRES: 20230110 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
